Your session is about to expire
← Back to Search
Ocrelizumab for Multiple Sclerosis
Study Summary
This trial is testing a new drug, ocrelizumab, on people with RMS or PPMS. The trial will last for 4.5 years, and participants will be given infusions of the drug every few weeks. The trial will test the effects of the drug on the participants' symptoms and on their biomarkers.
- Multiple Sclerosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
When was Ocrelizumab cleared by the FDA?
"Ocrelizumab received a score of 3 on our Power scale. This is due to the fact that this is a Phase 3 trial, and thus there is both evidence of efficacy and safety from multiple rounds of data."
What other medical studies involving Ocrelizumab have been completed?
"Legacy Health System; Clinical Research & Tech Ctr first studied ocrelizumab in 2008. Since then, there have been 16 completed studies and 29 studies are still recruiting patients. Many of these locations for active recruitment are in Saint Louis, Missouri."
Which patients would be ideal candidates for this clinical trial?
"This clinical trial is accepting 132 people with primary progressive multiple sclerosis between the ages of 18 and 55. Most notably, patients are required to meet the following criteria: At least one clinically documented relapse in the past year and/or at least one T1-weighted Gadolinium (Gd)-enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment, Disease duration from the onset of multiple sclerosis symptoms less than (<) 15 years in participants with an EDSS score greater than (>) 5.0 at Screening, Must meet"
Are more people needed for this experiment?
"This study is not recruiting patients at the moment. The earliest posting date was April 29th, 2016, with the most recent update on October 17th, 2022. 559 other trials are actively searching for participants that have multiple sclerosis, primary progressive. Additionally, 29 other studies are looking for patients that fit the criteria for Ocrelizumab."
At how many different sites can participants enroll in this research?
"Currently, this clinical trial is underway at 14 different sites. Some of these locations include Saint Louis, San Francisco and Chapel Hill. Please select the clinic nearest to you to avoid extensive travel if you enroll in the trial."
Could you please tell me if this clinical trial is only open to adults?
"This particular clinical trial is only looking for patients that fall between 18-55 years of age. Out of the 44 trials for people under 18 and 414 for people over 65, this is the only study with this age range."
Share this study with friends
Copy Link
Messenger